• Verapamil in Hypoxia-Driven Urothelial Inflammation

  2026-08-19

  Verapamil ((±)-Verapamil) is more than a cardiovascular reference compound. Evidence from an enzyme-induced hypoxia model positions it as a practical perturbation tool for studying duration-dependent ROS/TXNIP/NLRP3 signaling in urothelial cells, while its calcium-channel and P-glycoprotein pharmacology demands disciplined controls. This article translates those findings into a reproducible experimental and translational strategy.

• 25-Hydroxycholesterol Reprograms Immunosuppressive TAMs

  2026-08-19

  Xiao et al. identify a CH25H–25-hydroxycholesterol circuit that accumulates in tumor-associated macrophage lysosomes and activates AMPKα through GPR155–mTORC1 signaling. The resulting AMPKα–STAT6–ARG1 axis reinforces immunosuppression, while CH25H targeting improves T-cell surveillance and anti-PD-1 responses in tumor models.

• NSC-23766 Rac GTPase Inhibitor Workflows

  2026-08-18

  NSC-23766 is a selective Rac GTPase inhibitor for dissecting Rac1-dependent migration, barrier regulation, apoptosis, and tumor-cell phenotypes. This guide translates its mechanism into dose-matrix, breast cancer, endothelial, and troubleshooting workflows while separating evidence-backed findings from practical starting conditions.

• Mouse Tissue Lysis Kit K1038 Workflow

  2026-08-18

  The Mouse Tissue Lysis Kit K1038 simplifies preparation of mouse tail, toe, and ear lysates for direct PCR-based genotyping and DNA analysis. It is intended for molecular biology research and direct template preparation, not diagnostic, clinical, or medical use.

• MLN2238: Proteasome β5 Subunit Inhibitor

  2026-08-17

  MLN2238 is a reversible proteasome β5 subunit inhibitor with nanomolar activity against the chymotrypsin-like site. Its research value spans multiple myeloma research, lymphoma research, apoptosis studies, and proteotoxic-stress signaling, including the ROS–JNK–CREB pathway.

• Acetylspiramycin: From Biosynthesis to Assay Design

  2026-08-16

  Acetylspiramycin, or Spiramycin B, is more than a macrolide antibiotic: its defined chemical identity makes it a useful probe for connecting ribosomal pharmacology, antimicrobial resistance research, and host-response studies. This article translates biosynthetic evidence into practical assay-design decisions.

• MK-1775: Rethinking Wee1 Checkpoint Strategy

  2026-08-15

  A translational framework for using MK-1775 to connect Wee1 biology, checkpoint abrogation, response measurement, and p53-deficient tumor research.

• Tamsulosin and Postoperative Urinary Retention

  2026-08-15

  A systematic review and meta-analysis of 23 randomized controlled trials found that perioperative Tamsulosin significantly reduced postoperative urinary retention and improved maximum urinary flow rate. The study’s value lies in isolating evidence for one α1-adrenergic antagonist while clarifying which postoperative outcomes were and were not improved.

• PRMT5-Driven Splicing and Metabolic Vulnerability

  2026-08-14

  The reference study shows that MYCN-amplified neuroblastoma is highly dependent on PRMT5-regulated splicing, epitranscriptomic control, and glutamine metabolism. Its integrated use of transcriptomics, isotope tracing, molecular validation, and mouse models identifies a mechanistic route from PRMT5 inhibition to GLS protein loss and metabolic stress.

• BRD4–RAC1 Co-targeting Rewires Breast Cancer Signaling

  2026-08-14

  The 2021 reference study identifies combined BRD4 and RAC1 inhibition as a context-dependent strategy that suppresses breast cancer growth, migration, stemness, and tumorigenesis across molecular subtypes. Its mechanistic contribution is the connection of BRD4–RAC1 blockade to disruption of the c-MYC–G9a–FTH1 axis and reduction of HDAC1-associated chromatin signaling.

• SB 431542: ALK5 Inhibitor Workflow Guide

  2026-08-13

  SB 431542 provides a practical way to separate ALK5-dependent TGF-β responses from downstream changes in proliferation, motility, immune behavior, and neuroinflammation models. This workflow connects validated Smad2 pathway assays with hypothesis-driven studies inspired by recent Alzheimer’s disease research.

• PR-619 for DUB and Ubiquitination Research

  2026-08-13

  PR-619 is a reversible, cell-permeable DUB inhibitor that accumulates ubiquitinated proteins without directly blocking proteasomal catalytic activity. This article translates that distinction into practical workflows for cancer biology research, autophagy activation assays, neurodegenerative disease models, and hypothesis-driven immuno-oncology studies.

• GGFG Peptide: From Epigenetic Insight to Conjugate Design

  2026-08-12

  A translational framework for using Gly-Gly-Phe-Gly as a flexible linker in drug conjugation research, informed by mechanistic findings in MLL-rearranged leukemia and grounded in experimentally testable design principles.

• ZCL278: A Mechanism-First Cdc42 Assay Guide

  2026-08-12

  ZCL278 is a selective Cdc42 inhibitor for connecting biochemical activity with cell migration, neuronal morphology, and fibrosis-related signaling. This mechanism-first guide explains how the kidney fibrosis literature can sharpen assay design without overstating what the compound has demonstrated.

• WST-8 Glucose Uptake Assay Kit: Practical Guide

  2026-08-11

  A scenario-based guide to using the WST-8 Glucose Uptake Assay Kit, SKU K2303, for quantitative, non-radioactive cellular glucose uptake studies. It covers assay principles, controls, protocol parameters, interpretation, and practical product-selection criteria for metabolic, diabetes, and cancer research.

445 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page